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Stephen D. NimerOur knowledge of the molecular defects that
underlie the myeloid malignancies (ie, acute myeloge-
nous leukemia [AML], myeloproliferative neoplasms
[MPNs], and the myelodysplastic syndromes [MDS])
is advancing rapidly. Although some acquired muta-
tions are found in all 3 of these diseases, others are
seen primarily in just one of them. In this regard,
mouse models may be helpful in deciphering how
specific lesions contribute to common or unique fea-
tures of these diseases.
In human studies, the most abnormal DNA meth-
ylation patterns are found in MDS, and increasing
numbers of mutations (or haploinsufficiency) of the
genes involved in the epigenetic control of gene
expression are being discovered. This suggests that
epigenetic dysregulation may play a recurrent impor-
tant role in MDS, and may or may not be related to
the clinical efficacy of ‘‘DNA hypomethylating’’
agents, such as 5-azacytidine and 5-azadeoxycytidine,
in patients with MDS. In this review I discuss some
of the most recent molecular abnormalities found in
MDS patients, with an eye toward their potential
therapeutic importance.CYTOGENETIC ABNORMALITIES
Even though the recurring cytogenetic abnormali-
ties associated withMDS (eg, 5q-, 7q-, 20q-, trisomy 8)
have been known for many years, the genes affected by
these chromosomal interstitial deletions or numerical
changes have escaped characterization until recently.
Modern molecular studies have identified other re-
current genomic abnormalities (eg, small regions of
chromosome gain or loss and uniparental disomyMolecular Pharmacology and Chemistry Program, Sloan-
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changes are being identified, such as UPD of chromo-
some 4q, where the TET2 gene is located.TRANSCRIPTION FACTORS
Among the first chromosomal translocations
described in MDS patients are t(3;21)(q26;q22), which
rearranges the AML1 and EVI-1 genes, and t(5;12),
which fuses the TEL gene (on chromosome 12) with
the receptor PDGFRb gene (on chromosome 5). Gene
fusions or mutations that generate constitutively acti-
vated tyrosine kinases are more commonly found in
MPNs (eg, BCR–ABL in chronic myelogenous leuke-
mia, the FIP1L1–PDGFRA fusion in hypereosinophilic
syndrome) and in MDS with more proliferative disease
(eg, JAK2V617F in RARS-t). The translocations most
often involve transcription factors (TFs) or other tran-
scriptional regulators. The TFs AML1 and EVI-1
play critical roles in normal hematopoiesis and are
required for the unique effects of the AML1-MDS1/
EVI-1 fusion protein. The AML1 (or RUNX1) gene is
involved in various chromosomal translocations in
AMLor acute lymphoblastic leukemia; pointmutations
or deletions are found in theM0 subtype of AML and in
MDS, particularly in therapy-relatedMDS [1,2]. These
mutations generally generate loss-of-function mutants,
but some generate dominant negative proteins that can
inhibit the function of the remaining wild-type AML1
protein.
The EVI-1 gene encodes both the MDS1-EVI-1
and EVI-1 proteins via differential promoter usage.
EVI-1, but not MDS1-EVI-1, is transforming and can
block erythroid differentiation [3]. EVI-1 overexpres-
sion can cooperate with certain RUNX1 mutant pro-
teins to generate AML in mice, suggesting that both
play a multifaceted role in leukemogenesis [4]. MDS1-
EVI-1 can function as a transcriptional repressor, inter-
acting with several methyltransferases, including G9a
[5] and Suv39H1 [6]. PRDM16 (or MEL1) is an EVI-
1–like gene [7] that is also involved in a translocation
with RUNX1 [8]. PRDM16 interacts with the LSD1
histone demethylase [9]. Thus, both the RUNX1-
MDS1-EVI1 and the RUNX1-MEL1 (PRDM16)S11
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changing the normal H3-K4 methyl activation mark
(on RUNX1 target genes) to a demethylated H3-
K4 mark, thereby promoting H3-K9 methylation
and gene repression. Overexpression of a truncated
PRDM16 protein works in concert with loss of p53 to
induce AML [10], further suggesting that restoration
of H3-K4 trimethylation and inhibition of LSD1 and
H3-K9 methylation could be a therapeutic approach
forMDS and/or AML. Thismechanism also implicates
a loss of p53 function in myeloid leukemogenesis.EPIGENETIC DEREGULATION IN MDS
Silencing of gene expression can result from the
processes of histone deacetylation, DNA promoter
hypermethylation, and site-specific histone methyla-
tion. Thus, the enzymes that catalyze these processes
represent potential therapeutic targets. These enzymes
include the histone deacetylases, which remove acetyl
groups from lysine residues in histones (and nonhis-
tone proteins as well); the DNA methyltransferases,
which catalyze methylation at CpG islands within
the promoters of critical growth regulatory genes;
and the histone methyltransferases (HMTs), which
methylate arginine or lysine residues within histones
(and nonhistone proteins) and promote an open or
closed chromatin conformation.
TheMLL, NSD1, and NSD3 genes are all involved
in translocations inmyeloiddisorders andall encodepro-
teins with methyltransferase activity. These proteins
contain a SET domain, so-named because it is found in
the Su(var)3-9, E(z), and trithorax proteins. SET do-
mains contain HMT activity and are found in several
other cancer-related proteins, including the EZH2
gene, whichhas recently been found to bemutated in pa-
tients with MDS [11,12] and non-Hodgkin lymphoma
[13]. A second class of HMTs containing a PR domain
rather than a SET domain has been identified as well
[11,12].SPECIFIC GENETIC LESIONS
The molecular basis of 5q-MDS is being vigor-
ously explored, due, at least in part, to the perceived
potential of lenalidomide as a targeted therapy for
this disease. Two-thirds of transfusion-dependent pa-
tients with 5q-MDS become transfusion-independent
on lenalidomide therapy, and40% achieve amajor or
complete cytogenetic response [14]. Many genes have
been suggested to play a role in 5q-MDS via haploin-
sufficiency, a mechanism invoked because the deletion
of candidate genes has not been accompanied bymuta-
tions in the remaining allele. RPS14 is a promising
candidate 5q- gene, identified by Ebert et al. [15] using
an RNA interference screen that defined the hemato-poietic effects of knockdown of each of the 40 genes
located within the 5q-commonly deleted region
(CDR). MicroRNAs also have been implicated in 5q-
MDS, especially miR145 and miR146a, which may
trigger innate immune mechanisms that preferentially
promote the proliferation of the 5q-clones [16]. In
contrast, such genes as the cell cycle regulator
cdc25c, which controls the movement of cells from
G2 to M, may be important for the effects of lenalido-
mide in patients with 5q-MDS [17]. The effects of le-
nalidomide on innate immune cells could play a role in
its activity as well.TET2 MUTATIONS
TET2 mutations in MDS patients were first
described by Tefferi et al. (2009) and Jankowska et al.
(2009) [18,19]. These mutations occur in 22%-42%
of patients with chronic myelomonocytic leukemia
(CMML) and in 10%-26% of those with MDS.
Although DNA methylation on cytosine residues
with CpG islands was once considered an irrevers-
ible event, it appears that such enzymes as TET1,
TET2, and TET3 can convert methylcytosine to
hydroxymethylcytosine [20], which can then undergo
chemical reactions that yield unmethylated cytosine
residues. Antibodies that can recognize 5-hydroxyme-
thylcytosine have been generated and are being used
to quantify its level in normal and MDS bone marrow
cells. TET2 mutations likely result in aberrant DNA
methylation. TET proteins (and the jumonji family of
demethylases) use a-ketoglutarate as substrates for
their reactions.ASXL1 MUTATIONS
TheASXL1 gene is located on chromosome 20q11,
outside of the CDR identified in MPN and MDS
patients with del20q. Mutations in ASXL1 are found
in 11% of MDS patients [21] (higher in patients
with Refractory anemia with excess blasts) and in
40%-50% of CMML patients. ASXL1 has been re-
ported to inhibit retinoic acid signaling by interacting
with SRC-1, HP1, and LSD1. Based on recent studies
of a Drosophila polycomb repressive complex called
PR-DUB, it seems thatASXL1might function ina com-
plex that has histone-deubiquitinating activity [22]. The
biological importance of this activity has not yet been
established.EZH2 MUTATIONS
EZH2 is a SET domain-containing HMT that
methylates histoneH3 at lysine 27 (H3K27), establish-
ing a (repressive) mark that can be recognized by poly-
comb group proteins in the polycomb repressive
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PRC2, along with EED and SUZ12. EZH2 is overex-
pressed in breast cancer, prostate cancer, and non-
Hodgkin lymphoma, suggesting that it functions as
an oncogene. Yet mutations in EZH2 have been
reported in patients with MDS and non-Hodgkin
lymphomas, which may alter, but not completely elim-
inate, EZH2 function. Functional characterization of
these mutant EZH2 proteins is underway.MOUSE MODELS OF MDS
Mouse models of MDS include the heterozygous
NPM1/- mouse, which develops a MDS similar to re-
fractory anemia that can transform to acute leukemia.
Although the NPM gene is located on 5q, it is outside
the CDR, andNPMmutations generally are not found
in patients with MDS [23]. Another MDS model is
based on the overexpression of EVI-1 in murine
bone marrow cells. After a significant latency period,
the recipient mice develop MDS [24] with significant
erythroid defects but without increased blasts; these
mice do not develop acute leukemia. A third mouse
model, with an MDS phase that can progress to
AML, is based on overexpressing RUNX1 (AML1)
point mutant proteins in mouse bone marrow cells
[4]. There are other models as well, but perhaps the
best MDS model is based on overexpression of
NUP98-HOXD13; these transgenic mice develop
MDS that is fatal due to progressive cytopenias or
due to the development of AML (in50%), mirroring
the clinical disease.
The most recently published model represents
a technical tour de force. Barlow and coworkers
[25] took advantage of large-scale chromosome
engineering to generate the firstmousemodel of human
5q-MDS.These ‘‘5q-mice’’ display amacrocytic anemia
withmorphological evidence of erythroid andmegakar-
yocytic lineage dysplasia in the bone marrow, features
found in humans with this disorder [26]. These mice
are heterozygous for a region of mouse chromosome
18 (syntenic with the human 5q region) that contains
the RPS14 gene (which encodes a small ribosomal pro-
tein) that is essential for the proper processing of the 40S
subunit of the ribosome [15]. Because the p53 pathway
can be activated by defects in ribosomal biogenesis, Bar-
low and coworkers also investigated the link between ri-
bosomal stress, up-regulation of p53 function, and
apoptosis of erythroid precursors. By crossing the 5q-
mice with p53 null mice, these investigators rescued
the macrocytosis and the morphological evidence of
dysplasia, underscoring the important role of p53-
dependent mechanisms in the pathogenesis of 5q-
MDS [25,27,28].
MicroRNAs (miRNAs) are key regulators of mes-
senger RNA levels and translation, and their alteredexpression has been demonstrated in various cancers,
including the hematologic malignancies [29]. Starczy-
nowski et al. [30] reported that decreased expression of
miR-145 and miR-146a occurs in 5q-MDS patient
samples, and used mouse models to show that the
lack of these miRNAs can result in a 5q-MDS–like
syndrome. In an analysis of gene expressionmicroarray
data, Starczynowski et al. [30] implicated genes
involved in innate immunity as key targets of miR-
145 and miR-146a, which could possibly explain the
features of 5q-MDS, particularly the competitive
growth advantage of the MDS cells in the bone mar-
row compared with wild-type cells. Other studies
have shown that miR-145 can target the Fli-1 tran-
scription factor [31,32]; thus, miR-145 haploinsuffi-
ciency would cause increased Fli-1 expression, which
could help trigger the thrombocytosis seen in 5q-
MDS patients.CONCLUSION
A fundamental paradox is that although MDS
clones can take over the marrow space of an individual
with this disease, growing MDS cells in vitro or in
immunodeficient mice is very difficult. Several groups
have reported that abnormalities in stromal cells can
induce MDS (or AML) in otherwise normal bone
marrow cells [33]. Although this may not occur in pa-
tients, it seems clear that the basis for the proliferative
advantage and the progressive nature of this disease
will involve the interaction of hematopoietic stem cells
with their microenvironment. Much remains to be
determined about the pathogenesis of MDS, but the
recent identification of recurring genetic lesions
should help advance our understanding of this disease.ACKNOWLEDGMENTS
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